--- title: "Ocugen Raises Capital Through Convertible Senior Notes Offering" type: "News" locale: "en" url: "https://longbridge.com/en/news/285617510.md" description: "Ocugen, Inc. has completed a private offering of $115 million in 6.75% Convertible Senior Notes due 2034, generating approximately $99.5 million in net proceeds. The funds will be used to repay an existing loan and for general corporate purposes. The notes are convertible into common stock under certain conditions and include investor protections. Analysts rate OCGN stock as a Buy with a $7.00 price target, while AI analysis suggests a Neutral outlook due to high financial risk and ongoing cash burn." datetime: "2026-05-07T20:49:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285617510.md) - [en](https://longbridge.com/en/news/285617510.md) - [zh-HK](https://longbridge.com/zh-HK/news/285617510.md) --- # Ocugen Raises Capital Through Convertible Senior Notes Offering ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Ocugen ( (OCGN) ) just unveiled an announcement. On May 7, 2026, Ocugen, Inc. completed a private offering of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034, issued as unsecured senior obligations with detailed conversion, redemption and default provisions. The notes, initially convertible at a premium-equivalent price of about $2.68 per share and subject to Nasdaq share caps and stockholder approvals, were sold at 90% of par, generating roughly $99.5 million in net proceeds, of which about $32.7 million was used to fully repay and terminate an existing Avenue loan facility, with the remainder earmarked for general corporate purposes, reshaping the company’s capital structure and extending its debt maturity profile. The notes allow holders conversion into common stock after a specified date under defined conditions, while Ocugen retains optional redemption rights from 2029 if share-price thresholds are met. Investor protections include a 2032 put, fundamental change repurchase rights and customary events of default, underscoring a balance between Ocugen’s financing flexibility and institutional investors’ demand for security and potential equity upside. The most recent analyst rating on (OCGN) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page. **Spark’s Take on OCGN Stock** According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral. Overall score reflects high financial risk (negative equity and ongoing cash burn) partially offset by favorable earnings-call momentum around late-stage clinical progress and defined regulatory timelines. Technical signals are neutral-to-mixed and valuation is not supportive due to losses and no dividend. To see Spark’s full report on OCGN stock, click here. **More about Ocugen** Ocugen, Inc. is a U.S.-based biopharmaceutical company listed on The Nasdaq Capital Market. The company focuses on developing and commercializing therapies in its sector and accesses capital markets through debt and equity-linked securities to finance its operations and strategic initiatives. **Average Trading Volume:** 8,508,085 **Technical Sentiment Signal:** Sell **Current Market Cap:** $492.5M ### Related Stocks - [OCGN.US](https://longbridge.com/en/quote/OCGN.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) ## Related News & Research - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md) - [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md) - [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md) - [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md)